These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Disorders in the conversion of fibrinogen to fibrin in patients with multiple myeloma]. Lopaciuk S; Snigurowicz J; Rostkowska J; Pniejnia-Olszyński W; Powiertowska-Rezmer M Acta Haematol Pol; 1978; 9(3):157-64. PubMed ID: 102100 [TBL] [Abstract][Full Text] [Related]
3. Abnormal fibrin structure and inhibition of fibrinolysis in patients with multiple myeloma. Carr ME; Dent RM; Carr SL J Lab Clin Med; 1996 Jul; 128(1):83-8. PubMed ID: 8759939 [TBL] [Abstract][Full Text] [Related]
4. [Increased thrombin time in a patient with multiple myeloma]. Bohler A; Redondo M; Lämmle B Ther Umsch; 1999 Sep; 56(9):491-4. PubMed ID: 10517116 [TBL] [Abstract][Full Text] [Related]
5. Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Colwell NS; Tollefsen DM; Blinder MA Br J Haematol; 1997 Apr; 97(1):219-26. PubMed ID: 9136969 [TBL] [Abstract][Full Text] [Related]
6. Impaired thrombin generation in Reelin-deficient mice: a potential role of plasma Reelin in hemostasis. Tseng WL; Chen TH; Huang CC; Huang YH; Yeh CF; Tsai HJ; Lee HY; Kao CY; Lin SW; Liao HR; Cheng JC; Tseng CP J Thromb Haemost; 2014 Dec; 12(12):2054-64. PubMed ID: 25255925 [TBL] [Abstract][Full Text] [Related]
7. Analysis of a fibrin formation abnormality in a case of multiple myeloma. Soria J; Soria C; Samama M; Fine JM; Bousser J Scand J Haematol; 1975 Oct; 15(3):207-18. PubMed ID: 812173 [TBL] [Abstract][Full Text] [Related]
8. Kinetic model facilitates analysis of fibrin generation and its modulation by clotting factors: implications for hemostasis-enhancing therapies. Mitrophanov AY; Wolberg AS; Reifman J Mol Biosyst; 2014 Jul; 10(9):2347-57. PubMed ID: 24958246 [TBL] [Abstract][Full Text] [Related]
9. Fibrin, γ'-fibrinogen, and transclot pressure gradient control hemostatic clot growth during human blood flow over a collagen/tissue factor wound. Muthard RW; Welsh JD; Brass LF; Diamond SL Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):645-54. PubMed ID: 25614284 [TBL] [Abstract][Full Text] [Related]
10. Additive roles of platelets and fibrinogen in whole-blood fibrin clot formation upon dilution as assessed by thromboelastometry. Ninivaggi M; Feijge MA; Baaten CC; Kuiper GJ; Marcus MA; Ten Cate H; Lancé MD; Heemskerk JW; van der Meijden PE Thromb Haemost; 2014 Mar; 111(3):447-57. PubMed ID: 24258426 [TBL] [Abstract][Full Text] [Related]
11. Factor XIII deficiency enhances thrombin generation due to impaired fibrin polymerization - An effect corrected by Factor XIII replacement. Pitkänen HH; Jouppila A; Lemponen M; Ilmakunnas M; Ahonen J; Lassila R Thromb Res; 2017 Jan; 149():56-61. PubMed ID: 27902939 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of fibrin monomer polymerisation by myeloma immunoglobulin. O'Kane MJ; Wisdom GB; Desai ZR; Archbold GP J Clin Pathol; 1994 Mar; 47(3):266-8. PubMed ID: 8163700 [TBL] [Abstract][Full Text] [Related]
13. Effect of serum monoclonal protein concentration on haemostasis in patients with multiple myeloma. Huang H; Li H; Li D Blood Coagul Fibrinolysis; 2015 Jul; 26(5):555-9. PubMed ID: 25828972 [TBL] [Abstract][Full Text] [Related]
14. Interconnectedness of global hemostasis assay parameters in simultaneously evaluated thrombin generation, fibrin generation and clot lysis in normal plasma. Xin KZ; Chang WC; Ovanesov MV Thromb Res; 2016 Apr; 140():132-139. PubMed ID: 26632515 [TBL] [Abstract][Full Text] [Related]
15. Bleeding diathesis in multiple myeloma. Saif MW; Allegra CJ; Greenberg B J Hematother Stem Cell Res; 2001 Oct; 10(5):657-60. PubMed ID: 11672511 [TBL] [Abstract][Full Text] [Related]
16. An acquired cryoglobulinemia which inhibits fibrin polymerization in a patient with IgG kappa myeloma. Panzer S; Thaler E Haemostasis; 1993; 23(1):69-76. PubMed ID: 8477911 [TBL] [Abstract][Full Text] [Related]
17. β2 -Glycoprotein I binds to thrombin and selectively inhibits the enzyme procoagulant functions. Pozzi N; Acquasaliente L; Frasson R; Cristiani A; Moro S; Banzato A; Pengo V; Scaglione GL; Arcovito A; De Cristofaro R; De Filippis V J Thromb Haemost; 2013 Jun; 11(6):1093-102. PubMed ID: 23578283 [TBL] [Abstract][Full Text] [Related]
18. Differential inhibitory action of apixaban on platelet and fibrin components of forming thrombi: Studies with circulating blood and in a platelet-based model of thrombin generation. Pujadas-Mestres L; Lopez-Vilchez I; Arellano-Rodrigo E; Reverter JC; Lopez-Farre A; Diaz-Ricart M; Badimon JJ; Escolar G PLoS One; 2017; 12(2):e0171486. PubMed ID: 28192448 [TBL] [Abstract][Full Text] [Related]
19. The molecular localization of the ability of certain monoclonal immunoglobulins to interfere with fibrin polymerization. Wisløff F; Michaelsen TE; Kierulf P; Godal HC Thromb Res; 1985 Nov; 40(4):473-82. PubMed ID: 4082120 [TBL] [Abstract][Full Text] [Related]
20. Effects of platelets activated by different agonists on fibrin formation and thrombin generation. Muravlev IA; Dobrovolsky AB; Antonova OA; Khaspekova SG; Mazurov AV Platelets; 2023 Dec; 34(1):2139365. PubMed ID: 36325627 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]